echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > AACR 2022: NK Cells and Bispecific Antibody AFM13 Complexes Consistently Induce Lymphoma Remission

    AACR 2022: NK Cells and Bispecific Antibody AFM13 Complexes Consistently Induce Lymphoma Remission

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The complex of the bispecific antibody AFM13 with NK cells continued to induce remission in patients with relapsed CD30 + lymphoma
    , results from a phase I/II study presented Sunday at the American Association for Cancer Research (AACR) annual meeting .
    "Our preliminary results suggest that the activity and tolerability of the complex in this heavily previously treated patient population is promising and warrants further investigation," said Yago Nieto, who presented the study

    .

    + lymphoma

    AFM13 is able to target CD16A and CD30, pre-complexed with cord blood-derived allogeneic NK cells in CD30 + relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients with median prior treatment Line is 7
    .

    + The median prior line of therapy for these patients was 7 The median prior line of therapy for these patients was 7

    After undergoing immune cell dissection, subjects received two cycles of AFM13-NK cell complexes, up to 100 million cells/kg, administered to 13 patients and selected for Phase II evaluation
    .
    Subsequent 3 weekly infusions of AFM13 monotherapy were also administered, and response was assessed on day 28

    .

    immunity

    Of the 19 evaluable patients, 17 responded to treatment, resulting in an overall response rate (ORR) of 89%
    .
    These included all 13 patients treated at the recommended phase II dose levels, with 8 (62%) in complete remission (CR) and 5 in partial remission (PR)
    .
    Of the 8 CRs, 7 remained in complete remission after a median follow-up of 6.
    5 months, of which 2 remained in complete remission after 10 months, and 2 received autologous
    stem cell transplantation
    .
    At all dose levels, after a median follow-up of 11 months, progression-free survival and overall survival were 53 percent and 79 percent, respectively, the researchers said

    .

    Of the 19 evaluable patients, 17 responded to treatment, resulting in an overall response rate (ORR) of 89%
    .
    Of the 19 evaluable patients, 17 responded to treatment, resulting in an overall response rate (ORR) of 89%
    .
    stem cell

    Meanwhile, the therapy was well tolerated, with no cases of cytokine release syndrome, immune effector cell-related neurotoxicity, or graft-versus-host disease
    .

     

    Original source:

    Original source:

    https://firstwordpharma.
    com/story/5545475

    https://firstwordpharma.
    com/story/5545475
    https://firstwordpharma.
    com/story/5545475


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.